Journal
MUSCLE & NERVE
Volume 61, Issue 3, Pages 316-324Publisher
WILEY
DOI: 10.1002/mus.26772
Keywords
chronic inflammatory demyelinating polyneuropathy; CIDP; disability; outcome; prognosis
Categories
Funding
- Baxalta
Ask authors/readers for more resources
Introduction The effect of long-lasting immune-modulating therapy was studied in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods A population-based, cross-sectional study of treated patients referred to the Danish health-care system between 1985 and 2006. Results The 51 participating patients had a median disease duration of 16 (interquartile range, 14-21) years. Twenty-seven patients (53%) had discontinued therapy and 46 walked independently. Disability and isokinetic strength were impaired by 17% and 20%, respectively, as compared with matched control subjects. For a few patients long-term CIDP was associated with severe morbidity (6%) and even mortality (1%). Prolongation of time until start of therapy was associated with an increased burden of long-term disability. Discussion Long-term prognosis in treated CIDP is characterized by limited disability in the majority of patients. Disability is related to delay of therapy. Therefore, more attention should be given to early treatment start in CIDP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available